Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verteporfin PDT in Primary Breast Cancer
NCT02872064Phase 2Completed
- Sponsor
- University College London
- Start
- Jan 2013
- Primary completion
- Nov 2017
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of verteporfin in breast cancer, sponsored by University College London. Primary endpoint: Establish the minimum effective light dose at 1 month. Started Jan 2013; status: completed.
02
Drugs
verteporfin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02872064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872064.